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Bone homeostasis displays a circadian rhythm with increased resorption during the
night time as compared to day time, a difference that seems—at least partly—to be
caused by food intake during the day. Thus, ingestion of a meal results in a decrease
in bone resorption, but people suffering from short bowel syndrome lack this response.
Gut hormones, released in response to a meal, contribute to this link between the gut
and bone metabolism. The responsible hormones appear to include glucose-dependent
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), known as incretin
hormones due to their role in regulating glucose homeostasis by enhancing insulin
release in response to food intake. They interact with their cognate receptors (GIPR
and GLP-1R), which are both members of the class B G protein-coupled receptors
(GPCRs), and already recognized as targets for treatment of metabolic diseases, such as
type 2 diabetes mellitus (T2DM) and obesity. Glucagon-like peptide-2 (GLP-2), secreted
concomitantly with GLP-1, acting via another class B receptor (GLP-2R), is also part
of this gut-bone axis. Several studies, including human studies, have indicated that
these three hormones inhibit bone resorption and, moreover, that GIP increases bone
formation. Another hormone, peptide YY (PYY), is also secreted from the enteroendocrine
L-cells (together with GLP-1 and GLP-2), and acts mainly via interaction with the class
A GPCR NPY-R2. PYY is best known for its effect on appetite regulation, but recent
studies have also shown an effect of PYY on bone metabolism. The aim of this review
is to summarize the current knowledge of the actions of GIP, GLP-1, GLP-2, and PYY
on bone metabolism, and to discuss future therapies targeting these receptors for the
treatment of osteoporosis.
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INTRODUCTION—BONES
Bone is a tissue with very important mechanical functions,
providing rigidity, strength and shape, and is essential for
movement. However, in spite of its apparently static structure,
bone tissue is dynamic and undergoes a constant remodeling,
consisting of processes of bone resorption and bone formation.
Proper balance is controlled by the coupling of these two
processes, and involves a number of coordinated signaling
mechanisms. In normal bone remodeling, a balance between
bone resorption (mediated by osteoclasts) and bone formation
(mediated by osteoblasts) is maintained to ensure a constant
bone mass. An imbalance between bone resorption and bone
formation may occur under certain pathological conditions, and
lead to abnormal bone remodeling and the development of
bone disorders (1). Bone also has an important function as a
reservoir for calcium and phosphate, bound in the matrix as
hydroxyapatite, and bone tissue is, therefore, along with the
intestine and kidneys, important for the maintenance of proper
calcium levels (2–4).
Histologically, there are two main types of bone, cortical and
trabecular. These have different structure and properties. Cortical
bone has a highly organized, lamellar structure, providing planar
strength. Generally, bones have an outer layer of cortical bone
with trabecular bone beneath. The weight-bearing long bones,
such as the femur and humerus, mainly have cortical bone in
their shafts. Trabecular bone has a more irregular and less dense
structure, consisting of interconnecting bars, or trabeculae, with
bone marrow filling the gaps. The number of trabeculae has been
shown to be more important than their thickness in regard to the
strength of the bone (5).
Bone tissue consists of cellular elements within an
extracellular matrix. The cellular components are the osteoblasts,
the osteocytes and the osteoclasts. The bone-forming osteoblasts
derive from mesenchymal stem cells that differentiate into
osteoprogenitor cells, a process that is dependent on the
Wnt/β-catenin pathway. With age, the osteoblasts become
buried in the matrix and are now designated osteocytes.
These cells communicate with each other and with other cells,
particularly those on the surface of the bone tissue, through
dendritic processes in canaliculi in the bone, allowing them
to regulate bone-turnover in response to mechanical stress
(1). Osteoclasts are multinucleated cells, derived from the
macrophage/monocyte lineage, which resorb bone on the growth
surface. The differentiation into mature osteoclasts is dependent
on activation by the receptor activator of nuclear factor κB
(NF-κB) ligand (RANKL) and monocyte colony stimulating
factor (M-CSF) produced by the osteoblasts.
The remodeling of the bone involves a coordinated action
of a team of cells, referred to as a basic multicellular unit
(BMU). The osteoclast-mediated resorption and the osteoblast-
mediated formation are thought to be orchestrated by local
regulation within the BMU, as well as by systemic regulation
from outside the BMU. The local signaling within the BMU
is often presented as a complex network of regulation between
the different cell types, where the osteocyte population regulates
the activity of the osteoblast population, and the osteoblast
population, in turn, regulates the activity of the osteoclast
population and vice versa (Figure 1). Osteocytes regulate the
osteoblasts via signaling molecules including fibroblast growth
factor-23 (FGF-23), bone morphogenetic proteins (BMPs), and
sclerostin, whereas some of the key signaling molecules involved
in the osteoblastic regulation of the osteoclasts include RANKL,
that induces osteoclast activity, and osteoprotegerin (OPG), that
counters the effect of RANKL. Malfunctions in some of these
regulatory mechanisms are known to cause bone disorders;
mutations of FGF-23, for example, are known to cause autosomal
dominant hypophosphatemic rickets (ADHR). Some of these
regulatory factors, including RANKL and sclerostin, are targets
for therapies that aim to alter the balance between the osteoblast
activity and osteoclast activity in order to treat osteoporosis,
which is characterized by an imbalance between these activities.
When bone is resorbed, a carboxy-terminal telopeptide of type
I collagen (CTX) is liberated and released into the blood stream.
Levels of circulating CTX are, therefore, used as a biomarker
for bone resorption. CTX levels show diurnal variation, peaking
during the night-time, and showing a nadir in the late afternoon.
As fasting is associated with a flattened circadian rhythm (6), with
the day-time decline in CTX levels being eliminated, ingestion
of food seems to be the explanation for the daytime suppression
(7, 8). Bone formation can be assessed by measurements of
an amino-terminal propeptide of type 1 procollagen (P1NP)
or by measuring the protein osteocalcin, which is secreted
from osteoblasts.
THE GUT-BONE AXIS
The gut and the bones are connected through the gut-bone axis,
and this interaction is mediated by hormones secreted from the
intestine. These hormones are secreted in response to food intake
and causes a decrease in bone resorption (7–9), and are thus
mediators of the adaptation of bones to nutrient availability. Bone
resorption is increased during the night as compared to the day,
and this day-time suppression is eliminated by fasting, further
affirming the role of the gastrointestinal hormones in the control
of bone homeostasis. Many hormones are secreted from the gut
[for a recent review see Gribble and Reimann (10)], but the
focus of this review will be on the incretin hormones glucose-
dependent insulinotropic polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1), as well as glucagon-like peptide-2 (GLP-2)
and peptide YY (PYY).
GIP (secreted from enteroendocrine K-cells) and GLP-1
(secreted from L-cells) have been extensively studied with respect
to their effects on glucose metabolism asmediators of the incretin
effect: i.e., the enhanced insulin secretion which occurs when
glucose is ingested orally compared to i.v. glucose injection (11–
14). For this reason, there has been much interest in their use
in the treatment of type 2 diabetes mellitus (T2DM) and obesity,
and many widely used drugs for T2DM, such as liraglutide and
exenatide, act as GLP-1 receptor agonists (GLP-1RA). GLP-2 is
also released from the L-cells in the small intestine, but in contrast
to the glucose-lowering effects of GLP-1 (and GIP), GLP-2 is
mostly known as an intestinotropic factor (15, 16). GIP, GLP-1,
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FIGURE 1 | Bone remodeling is a process that takes place in the bone remodeling unit (BMU). BMU consists of bone resorbing osteoclasts (OC), bone forming
osteoblasts (OB), and osteocytes. The process is regulated by local signals between the cells and by external stimuli. OBs stimulate OC precursors to differentiate into
mature OCs by secreting monocyte colony stimulating factor (M-CSF) and RANKL, but may also inhibit the same cells by secreting osteoprotegerin (OPG) that
scavenges RANKL, preventing it from binding to the RANK receptors on the OC precursors. OBs are derived from mesenchymal stem cells, a process that is
dependent on the Wnt/β-catenin pathway. This pathway is inhibited by sclerostin, which is secreted from osteocytes. Several other factors which affect bone
remodeling are mentioned in the text (FGF-23, BMP), but are not shown in this figure.
and GLP-2 are all believed to protect against bone resorption,
either via direct effects on the bone cells, or indirectly. PYY
is co-secreted with GLP-1 and −2 from the L-cells and also
affects bone metabolism, possibly by inhibiting formation. These
hormones are involved in the gut-bone axis, as reviewed below
and summarized in Table 1.
Glucagon-Like Peptide-2 (GLP-2)
GLP-2 is co-secreted with GLP-1 from intestinal L-cells in
the small and large intestine upon nutrient ingestion. GLP-
1 and GLP-2 are derived from pro-glucagon which is post-
translationally processed by pro-hormone convertase 1/3 in the
L-cells (58–60). Intact GLP-2(1-33) (referred to as GLP-2 in rest
of this review) is cleaved by the ubiquitous protease dipeptidyl
peptidase-4 (DPP-4) at the alanine in position 2, with a half-life
in plasma of approximately 7min, forming the main degradation
product GLP-2(3-33) (61). This variant has been shown to act
as a low affinity, partial agonist with competitive antagonistic
properties on the GLP-2 receptor in vitro (62). A prolonged half-
life of GLP-2 can be achieved by substitution of the alanine in
position 2 or by the use of DPP-4 inhibitors (63–65).
The GLP-2 receptor (GLP-2R) belongs to class B G protein-
coupled receptors (GPCR). Based on animal studies, it is
predominantly expressed in the gastrointestinal tract in enteric
neurons (66, 67), but has also been found in the central nervous
system and may be sparsely expressed in the lungs (20, 66).
The exact localization of the GLP-2R in humans is however
still uncertain due to lack of good antibodies for immuno-
localization, as well as the low levels of GLP-2R expression in
cells outside the gastrointestinal tract; extrapolation from other
species may be risky because of differences between species (68).
GLP-2 has trophic effects on the intestine. In mice,
administration of GLP-2 promotes growth of the small and large
intestine, whereas co-administration of GLP-2 and high doses of
GLP-2(3-33) results in a reduced response (62). GLP-2 acts on the
intestinal crypt compartment, stimulating proliferation, but also
inhibits apoptosis (69). Accordingly, GLP-2 has been studied in
patients with short bowel syndrome (SBS) (70) and, since 2012, a
DPP-4 resistant GLP-2 analog (teduglutide) has been used in the
treatment of SBS. GLP-2 also appears to improve the intestinal
barrier function, up-regulate glucose transport and increase
mesenteric blood flow. Although less well-established, it has
also been reported to inhibit food intake and promote neuronal
proliferation (17, 18, 71, 72). The mechanisms underlying the
effects of GLP-2 are not well-described, although they seem to be
mediated indirectly through the ErbB system (73), keratinocyte
growth factor (KGF) (74) and, perhaps, insulin-like growth
factor-1 (IGF-1) (69).
GLP-2’s Effect on Bones
In 2001, the first human study revealed that 5-weeks treatment
with natural GLP-2 significantly increased spinal areal bone
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TABLE 1 | Summary of the known effects of the gut hormones GLP-2, GIP, GLP-1, and PYY on bone metabolism.
Hormone Study
design
Species Finding References
GLP-2 In vivo Human GLP-2 inhibits bone resorption (measured as CTX) with only minimal effects on bone
formation (measured as osteocalcin or P1NP). Four months of GLP-2 treatment increases
hip BMD in postmenopausal women
(7, 17–19)
Mouse None. No studies report effects of GLP-2 on bone remodeling in the mouse
Rat None
In vitro Human The GLP-2R has not been identified in human bone cells, though one study reports
GLP-2R expression on the cell lines MG-63 and TE-85 (reflecting immature human
osteoblasts)
(20)
Mouse None
Rat None
Summary GLP-2: GLP-2 does not affect bone remodeling in rodents either In vitro or In vivo. In humans, GLP-2 acutely inhibits bone resorption, and 4 months of
GLP-2 treatment increases hip BMD in postmenopausal women
GIP In vivo Human GIP reduces CTX independently of insulin
Loss-of function GIPR gene polymorphism is correlated to a decreased BMD and
increased fracture risk
(9, 21–23)
Mouse Lack of GIP signaling or peptide alters the bone structure in a negative direction, but
findings in different studies are not always consistent
(24–27)
Rat GIP Improves bone density in OVX rats and cortical bone properties (28, 29)
In vitro Human GIP reduces osteoclast formation and resorption
In osteoblastic cell lines, GIP increase stimulates ALP and PINP, and diminishes cell death
(20, 30–32)
Mouse GIP inhibits PTH induced resorption and stimulates ALP and mineralization in osteoblasts (33, 34)
Rat None
Summary GIP: GIP has a direct effect on regulation on bone metabolism with anabolic effects on osteoblasts and anti-resorptive effects on osteoclasts
GLP-1 In vivo Human GLP-1 has positive effects on bone metabolism, possibly through increased formation. No
effect on plasma CTX concentrations
(7, 22, 35)
Mouse Studies in mice show that treatment with GLP-1RAs have protective effects against
OVX-induced or diabetes-induced bone loss
(36, 37)
Rat GLP-1 has positive effects on bone strength and quality, and protects against bone loss. It
causes an increase in bone formation parameters and a decrease in bone resorption
parameters
(38–44)
In vitro Human The receptor has been found on some osteoblastic cell lines. GLP-1 also increases cell
viability and promotes osteogenic differentiation of BMSCs
(20, 38, 40,
45)
Mouse The receptor has been found in mouse osteoblast-like cells. In most studies, GLP-1 leads
to an increase in differentiation and proliferation of osteoblasts, and it also exerts effects
on osteoclasts
(37, 46–49)
Rat The GLP-1R has been found on rat osteoblasts and osteocytes, and GLP-1 affects the
osteoblastic differentiation and regulate osteocyte protein production
(39, 40)
Summary GLP-1: GLP-1 directly affect bone cells, and regulates bone turnover by increasing formation and decreasing resorption
PYY In vivo Human Inverse relationship between plasma PYY and BMD in populations with weight gain (↓PYY
and ↑BMD in obesity) and weight loss (↑PYY and ↓BMD in patients with anorexia and
after gastric bypass surgery)
(50–52)
Mouse Direct effect of PYY on osteoblast and osteoclast activity with a negative relationship
between PYY and osteoclast activity
PYY−/− mice exhibit an increase in bone mass and strength, although controversies exist
Regulation of bone resorption and formation seem to occur via Y1, Y2, and Y6 receptors
(53–57)
Rat None
In vitro Human None
Mouse PYY signaling in osteoblasts occurs via Y1 receptors, but no Y receptors seem to exist on
osteoclasts
(54)
Rat None
Summary PYY: PYY may play a role in bone mass regulation as evident from association studies in populations with altered energy balance. Support of this originates
from rodent studies
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mineral density (aBMD) in SBS patients with no terminal
ileum and no colon (70, 75). Shortly hereafter, Henriksen et al.
showed that GLP-2 administered subcutaneously (s.c.) in doses
ranging from 200, 400, and 800 µg in healthy postmenopausal
women dose-dependently reduced bone resorption (measured
as CTX), while the bone formation (measured as osteocalcin)
was unaffected (7). Moreover, GLP-2 s.c. injected at bedtime also
inhibited the nocturnal bone resorption (CTX) (76). In a 14-day
study, daily bedtime injections of 1.6 and 3.2mg GLP-2 were
well-tolerated and reduced CTX with no effect on markers of
bone formation (osteocalcin and P1NP) (19). Finally, 4 months
of GLP-2 treatment resulted in a dose-related significant increase
in hip aBMD of about 1%, with no signs of GLP-2 antibodies
or tachyphylaxis (17). In contrast to the earlier findings that
GLP-2 increased aBMD in SBS patients (75), Gottschalck et al.
reported that reductions in CTX after exogenous GLP-2 requires
an intact small intestine, indicating an indirect effect of GLP-
2 involving the intestine (77, 78). Additionally, they found
that GLP-2 decreased PTH in control participants with an
intact intestine, making PTH a potential mediator of the GLP-
2 induced decrease in CTX (77). In 2013, Askov-Hansen et al.
investigated the effect of high concentration (achieved by i.v.
injection) vs. prolonged exposure (achieved by s.c. injection)
of GLP-2 in healthy participants. They found that prolonged
exposure was more effective in reducing circulating CTX levels
than acute high concentrations. Pre-treatment with the DPP-
4 inhibitor sitagliptin increased plasma levels of GLP-2, but
had no additional effects on CTX (18). Intriguingly, despite the
impact of GLP-2 on osteoclast activity, the GLP-2R has not been
identified in human osteoclasts, or in any other bone-related cell
type, though Pacheco-Pantoja et al. found the receptor to be
expressed in the immature human osteoblast cell lines MG-63
and TE-85 (20).
In summary, GLP-2 markedly inhibits bone resorption with
only minimal effects on bone formation, resulting in an increased
bone mineral density. Judged from existing studies, only supra-
physiological doses of exogenous GLP-2 reduce bone resorption
(CTX), but the mechanism by which GLP-2 affects bone
metabolism is still unknown. It might act directly on bone cells or
the effect might be mediated indirectly, possibly involving other
intestinal factors.
Glucose-Dependent Insulinotropic
Polypeptide (GIP)
GIP is a 42 amino acid peptide secreted upon food ingestion from
the enteroendocrine K-cells located primarily in the proximal
small intestine (71). Together with GLP-1, it is known as an
incretin hormone, being responsible for approximately 50–70%
of the insulin response to oral glucose administration in healthy
humans (71). GIP(1-42) is, like GLP-2, N-terminally cleaved
by DPP-4 generating the metabolite GIP(3-42) (79), thereby
resulting in a plasma half-life of active GIP of 4min in humans
(80). For research purposes, several DPP-4 resistant GIP analogs
have been produced, such as N-AcGIP, Pro3GIP, and D-Ala2-
GIP. Moreover, a naturally occurring C-terminally truncated
variant, devoid of the last 12 amino acids, GIP(1-30)NH2, acts
as full agonist for the human GIP system (81). DPP-4 cleavage
of this compound results in GIP(3-30)NH2, a high affinity
competitive antagonist for the GIP system with proven activity
in humans (81–83).
The GIP receptor (GIPR) belongs to the class B GPCRs,
and stimulates the GαS adenylyl-cyclase-cAMP-PKA pathway.
It is expressed in a wide range of tissues and organs,
the most important being the endocrine pancreas, adipose
tissue, bone, and several CNS regions (71). Accordingly, GIPR
signaling has been demonstrated in pancreatic α- and β-
cells (84), bone cells (30), adipocytes (85), and hippocampal
neural cells (86).The GIP system is less conserved among
species compared to the GLP-1 system (87, 88). Thus, the
sequence homology of the GIPR between rodents and humans
is only 81%, and the GIP peptide has 2 and 3 amino acid
substitutions, respectively, in rats and mice compared to human
GIP (88, 89). The efficacy of human GIP on rat and mice
GIPRs is only 75 and 60%, respectively, of those of rat
and mouse GIP, respectively. This information is relevant for
in vivo and in vitro tests of the GIP system in different
species (89).
Due to a markedly impaired insulinotropic effect of GIP in
T2DM patients (putatively due to a desensitization of the GIP
system) (90), the focus for GIP research has changed somewhat
from pancreatic β-cell stimulation and glucose homeostasis to
other areas, such as metabolism of bones and adipocytes, and
neural diseases.
GIP’s Effect on Bones
The GIPR is expressed in both osteoblast- and osteoclast-derived
cell lines (20, 46), and in murine primary cultures of osteoclasts
and osteoblasts (33, 34). Aoyama et al. found that the expression
of the GIPR increased upon increasing glucose concentrations
in the media (46). Expression of the GIPR has, moreover, been
verified on human bonemarrow-derivedmesenchymal stem cells
(BMSC) (31).
The osteoblastic cell lines vary in the degree of their
maturity, a difference that has been suggested to correlate
with GIPR expression. Moreover, the anabolic impact of GIP
stimulation on bone parameters such as alkaline phosphatase
(ALP), P1NP and cell viability varies between cell lines (20). GIP
increases intracellular calcium [Ca2+]i and cAMP, and increases
expression of P1NP and ALP activity (30). It also increases the
expression of c-Fos, an important factor in bone cell proliferation
and differentiation (45). Furthermore, GIP improves collagen
maturity and fibril diameter in a cAMP dependent manner
(91), and stimulates both ALP and mineralization in primary
osteoblast cultures from murine BMSC (34). Finally, GIP
attenuates caspase 3/7 activity and, thereby, diminishes cell
death in both hBMSC and an osteoblastic cell line (31). In
primary murine osteoclast cultures, GIP inhibits PTH-induced
bone resorption (33). Another study showed that GIP reduces
osteoclast formation and resorption in primary human and
murine cultures, and this reduced differentiation is independent
of the conventional adenylyl-cyclase-cAMP-PKA pathway. GIP
decreased the RANKL-induced [Ca2+]i increase and calcineurin
activity, and decreased nuclear translocation of the RANKL
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downstream target, NFATc1, which is important for terminal
osteoclast differentiation (32).
The first in vivo study was conducted in 2001, where
Bollag et al. showed a positive impact of native GIP on bone
density in ovariectomized (OVX) rats (28). Since then, many
studies have been performed using DPP-4 resistant peptides
and genetically modified mice with either receptor knock-out
(KO), congenital overexpression or deficiency of the GIP peptide.
The DPP-4 resistant peptides all show either anabolic or anti-
resorptive properties. N-AcGIP, for example, improved cortical
bone properties in rats and decreased osteoclast mediated bone
resorption in OVX mice, as seen by a reduction in both the
number of osteoclasts and the resorption marker CTX (29, 32).
In a type 1 diabetes (T1DM) mouse model, short term treatment
with D-Ala2-GIP, prevented a reduction of bone formation
parameters and at tissue level, it improved mechanical properties
(36). A peptide hybrid of GIP and oxyntomodulin, stimulating
both GIP, GLP-1, and glucagon receptors, also improved cortical
bone strength in a T2DMmouse model (92).
Two variants of GIPR KOmice exist, varying in the amount of
exons deleted. Both variants have compromised bone properties,
but some of the results are conflicting. The first GIPR KO mouse
characterized, with deletion of exon 4–5, showed decreased bone
formation parameters such as aBMD, bone mineral content
(BMC), trabecular bone volume, ALP and osteocalcin, and
increased resorptive parameters, such as increased numbers of
osteoclasts and increased urinary elimination of the resorption
marker, deoxypyridinoline (24, 25). The other GIPR KO mice,
with deletion of exon 1-6, showed decreased bone strength
and cortical thickness, and increased bone resorption, but they
also had an increased number of osteoblasts and a reduced
number of osteoclasts (26, 27). The double incretin KO mouse,
a combination of a GIPR KO and GLP-1R KO, showed
reduction in the cortical properties and a reduced strength of
the bones (93). Congenital deficiency of the GIP hormone was
similarly consistent with an important role of GIP for bone
metabolism, showing decreased bone volume and number of
trabeculae, and increased osteoclast surfaces (94). Conversely,
overexpression of GIP was associated with increased formation
of bone, with an increase in bone mass, number of osteoblasts,
osteocalcin levels, and inhibited bone resorption, as indicated
by decreased pyridinoline crosslinks and decreased number of
osteoclasts (34, 95).
In an early human study evaluating the effects of a brief
intravenous injection of GIP, there were no apparent effects on
bone resorption (7). A more recent study showed a 50% decrease
in CTX upon oral glucose ingestion, and 30% decrease upon
intravenous glucose administration, thus with a larger decrease
in the presence of high levels of incretin hormones (9). Two
subsequent studies showed a robust direct inhibitory effect of GIP
infusion on CTX at both low, eu-, and hyperglycemic levels (21),
and that the reduction of CTX by GIP was independent of insulin
(22). Moreover, a loss-of function GIPR gene polymorphism
(E354Q) was correlated with decreased aBMD, as analyzed by
DXA-scans in a 10 year follow up study of 1424 perimenopausal
women, and an evaluation of registered fractures over a period of
16 years showed a 50% increased fracture risk (23).
Overall, the studies in both humans and rodents indicate GIP
to be a pivotal and direct regulator of bone metabolism, with
direct anabolic effects on osteoblasts and anti-resorptive effects
on osteoclasts.
Glucagon-Like Peptide 1 (GLP-1)
GLP-1 is encoded within the proglucagon gene, which also codes
for glucagon and GLP-2. In the α-cells of the pancreas, the
proglucagon peptide is cleaved by prohormone convertase 2
(PC2), yielding glucagon. In the intestinal L-cells, PC1/3 cleaves
proglucagon to give the peptides, GLP-1 (PG78-107) (58, 59) and
GLP-2. GLP-1 is found in a glycine-extended form, GLP-1 (7-37),
which can be C-terminally amidated to give GLP-1 (7-36 NH2)
(59). It is released primarily in response to nutrient intake, and is
less affected by endocrine and neuronal factors. Thus, there is no
apparent “cephalic phase” for the meal-induced response (96). As
for GIP andGLP-2, GLP-1 is degraded by the enzymeDPP-4 (97),
which cleaves it after its alanine in position 2, giving it a half-life
<2min (61, 71, 97–99).
The GLP-1R is a class B GPCR, related to the GIP-, GLP-
2- and glucagon receptors and like these, it mainly couples to
Gαs (71). Although it is internalized, desensitization may not
occur in vivo (100). The GLP-1R is found in a variety of tissues,
amongst them, the pancreas and CNS, where it regulates release
of glucoregulatory hormones and appetite, respectively. GLP-1
acts on the pancreatic β-, α-, and δ-cells, where it stimulates
insulin secretion, inhibits glucagon secretion and stimulates
somatostatin release, respectively. Moreover, GLP-1R activation
in the CNS leads to decreased food intake and weight loss
(14), while in the stomach, GLP-1 inhibits gastric motility and
acid secretion (71). Due to these beneficial effects of GLP-1R
activation onmetabolism, several drugs have been developed that
act on the GLP-1 receptors, including the GLP-1RAs liraglutide,
dulaglutide and exendin-4, used in the treatment of T2DM and
obesity (101).
GLP-1’s Effect on Bones
Several studies indicate that GLP-1 has an effect on bone
homeostasis, although the exact mechanism involved remains
unclear. The GLP-1R has been found on immature osteoblastic
TE-85 and MG63 cells, but not in the Saos2 cell line (20). It
was also found in mouse osteoblast-like MC3T3-E1 cells (46, 47),
with one of the studies showing that its expression increases
with higher glucose concentrations in the media (46). In another
study, a GLP-1 receptor distinct from the classical pancreatic-
type receptor was found on MC3T3-E1 cells (102). In a study
by Meng, the receptor was found in bone marrow stem cells
(BMSC). These cells can differentiate into osteoblastic cells, but
the GLP-1R has not been found in primary osteoblasts (38),
or on the osteocyte-like MLO-Y4 cells (39). Pereira et al. (37)
found that the GLP-1R was expressed in mouse bone and bone
marrow, and in primary osteoblasts and osteoclasts, and also
in the IDG-SW3 osteocytic cell line, but not in the MLO-Y4
osteocytic cell line.
In vitro experiments show that activation of the GLP-1R
is important in bone metabolism. In one study by Pancheco-
Pantoja, GLP-1 increased cell viability and decreased P1NP
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secretion in two osteoblastic cell lines, TE-85, and MG-63
(20). In another study, they found that GLP-1 induces c-
Fos expression (a gene important in bone cell proliferation and
differentiation), in osteoblastic TE-85 cells, with a peak induction
after 60min (45). In mouse osteoblast-like MC3T3-E1 cells, the
GLP-1RA, exendin-4, increased proliferation, differentiation,
and mineralization through a MAPK pathway (47). Likewise,
liraglutide, increased proliferation and differentiation in
mouse osteoblast-like MC3T3-E1 cells in one study (47, 48),
but in another study, where the cells were cultured in a
commercial osteogenic differentiation medium, liraglutide
inhibited differentiation, as measured by ALP and osteocalcin
in both studies (49). In BMSCs, GLP-1 inhibits adipogenic
differentiation, while it promotes osteogenic differentiation
(38, 40). Pereira et al. found that both exendin-4 and liraglutide
increased osteoclast numbers when added to osteoclast precursor
cells derived from mouse bone marrow, while addition to
mature osteoclasts reduced the resorbed area (39). In addition,
GLP-1RAs have been shown to affect osteoclasts, stimulating
their differentiation, but reducing the resorbed area (37), and
reducing SOST/sclerostin expression in osteocyte-like MLO-Y4
cells (39).
In vivo, there are multiple studies in rodents establishing GLP-
1’s role in bone metabolism. In ovariectomized mice, treatment
with exendin-4 and liraglutide both had positive effects on
trabecular bone, but no effect on cortical bone. Exendin-4,
but not liraglutide, caused an increase in calcitonin, and a
decrease in serotonin, while both agonists increased osteoclast
differentiation, but reduced the resorbed area (37). In a study
in streptotozin-induced T1DM mice, short-term treatment with
liraglutide had no effect on bone loss, assessed by micro-CT
of trabecular microstructure, or bone formation parameters. It
did, however, improve tissue material properties (36). Moreover,
both GLP-1R KO and double-incretin receptor KO mice show
decreased bone quality and strength and reduced cortical area, as
well as decreased collagen maturity (93, 103, 104).
Treatment with GLP-1 in normal, insulin-resistant and type-2
diabetic (T2DM) rats, restored the impaired trabecular structure,
and while osteocalcin and osteoprotegerin increased in all three
groups, RANKL only increased in the T2DM rats (41). In
hyperlipidic rats that displayed osteopenia, short-term treatment
with GLP-1 or exendin-4 both reversed the decrease in bone
mass and quality, while levels of osteocalcin and osteoprotegerin
increased (42). Studies in ovariectomized rats have demonstrated
that treatment with the GLP-1RA liraglutide improved trabecular
number, volume and thickness, and increased aBMD compared
to control rats (40), while exendin-4 treatment increased aBMD
and BMCmeasured by DXA, and improved trabecular structure,
assessed bymicro-CT, and increased bone strength. Gene analysis
also revealed that exendin-4 treatment increased the bone
formation markers ALP, osteocalcin, and P1NP, while decreasing
the bone resorption parameter CTX (43). Liraglutide treatment
of the spontaneously diabetic Goto-Kakizaki rats restored the
impaired aBMD, and gene analysis showed an increase in
bone formation parameters (44), while treatment with exendin-
4 in rats with unloading-induced osteoporosis also improved
trabecular structure, aBMD and bone strength (38). Exendin-4
treatment of T2DM OLETF rats also increased femoral aBMD,
while reducing sclerostin and increasing osteocalcin (39).
Results from human studies are inconsistent. A randomized
controlled study by Iepsen et al. showed that liraglutide had
beneficial effects on weight-loss-induced bone loss. After an 8-
week weight-loss program, 37 women were divided into a control
group (19 women) and a group receiving liraglutide (18 women)
in the 52-week weight-maintenance phase. BMC, measured by
DXA scan, decreased significantly in the control group, but not
in the liraglutide group, whereas P1NP increased significantly in
the liraglutide group, but not the control group, indicating that
the protective effects are mediated by increased bone formation.
There was no effect on bone resorption, measured by plasma
CTX (35), which is in accordance with an earlier study by
Henriksen et al., where subcutaneous GLP-1 treatment had no
effect on CTX in seven healthy participants (7).
As GLP-1 analogs are already in use for the treatment of
T2DM, there are meta-analyses looking into the correlation
between liraglutide and exenatide treatment and the risk of
fractures. Studies on T2DM patients treated with GLP-1R
agonists found they were not associated with any change
in aBMD (105) and the risk of bone fractures was not
altered (106). However, in another meta-analysis of randomized
controlled trials, a decreased risk of fragility fractures with
liraglutide, but an elevated risk with exenatide treatment was
found (107).
In conclusion, multiple studies have demonstrated an impact
of GLP-1 on bone metabolism involving both an activation of
osteoblast function and an inhibition of osteoclasts.
PYY
Peptide YY (PYY) is another hormone secreted from the L-cell
in the postprandial state. PYY is often co-secreted with GLP-1
and GLP-2 (108) in proportion to caloric intake, and decreases
food intake via appetite-inhibiting actions which involve the
hypothalamic arcuate nucleus. It belongs to the pancreatic
polypeptide family together with neuropeptide Y (NPY) and
pancreatic polypeptide (109), and is secreted as the 36-amino-
acid molecular form PYY1−36. After secretion, PYY1−36 is
degraded by DPP-4 to form PYY3−36 (109).
In general, the different PYY molecular forms have different
half-lives and act via the four different G protein-coupled Y
receptors to which they bind with different affinities. PYY1−36
binds to the Y1, Y2, and Y5 receptors, whereas PYY3−36 is
highly selective for the Y2 receptor. This leads to opposing
effects on appetite and possibly also on glucose homeostasis,
as reviewed previously (110). PYY3−36 is responsible for the
anorexigenic actions of PYY, as documented in infusion studies
(111, 112) and together with GLP-1, seems to play a role in
the decreased food intake and major weight loss seen after the
bariatric surgery procedure, Roux-en-Y gastric bypass (111, 113).
Meal-induced PYY secretion is blunted in obese participants,
but the anorexigenic effect of PYY seems intact (114). COOH-
terminally truncated PYY metabolites, PYY1/3−34, have recently
been described in humans (115). The biological impact of these
metabolites remains to be elucidated, but PYY1/3−34 has no
affinity for the Y2 receptor (115).
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TABLE 2 | Current pharmacological treatment of osteoporosis.
Type Name Mechanism
ANTI-RESORPTIVE
Bisphosphonates Alendronate
Ibandronate
Risedronate
Zolendronic
acid
Binds to hydroxyapatite in the extracellular matrix and causes
osteoclast cell death by inhibiting the enzyme farnesyl
pyrophosphate synthase, disrupting the cytoskeletal structure
Estrogen/SERM Raloxifene Binds to the estrogen receptor, which has anti-catabolic
effects
Calcitonin Anti-resorptive effects (in animals)
Antibody mediated Denosumab Scavenges RANKL, preventing it from stimulating osteoclast
precursor differentiation and maturation
ANABOLIC
PTH-analog (1-34) Teriparatide Hormone replacement therapy: intermittent increase in
plasma PTH-levels activates osteoblasts. Daily injections
PTH-analog (1-84) Natpara Hormone replacement therapy—long term action
Pharmacological treatment of osteoporosis can be divided into anti-resorptive and anabolic drugs. Bisphosphonates are the most widely used drug for treating osteoporosis. Strontium
ranelate is not approved by the FDA, and only restricted use by the EMA, due to severe side-effects, such as increased risk of myocardial infarction and skin reactions. Teriparatide is the
only marketed anabolic drug, and mimics endogenous parathyroid hormone (PTH). Intermittent increases in plasma-PTH have anabolic effects, but continuously elevated levels, such
as in hyperparathyroidism, have catabolic effects. Several new drugs are being developed, aimed at specific molecules involved in the bone remodeling process, such as inhibitors of
cathepsin K (an enzyme secreted from osteoclasts, necessary for the resorption process) and inhibitors of the Wnt/β-catenin-pathway inhibitors sclerostin and dickkopf-1.
FIGURE 2 | The gut hormones GLP-2, GIP, GLP-1, and PYY, have been shown to affect bone metabolism. The osteoblast increases its activity in response to GIP
and GLP-2 (anabolic effects), and decreases its activity in response to PYY (catabolic effects). The exact mechanism of GLP-2 remains to be elucidated. GLP-2 has
been shown to be anti-resorptive in vivo, an effect which may be direct or indirect. GIP decreases osteoblast activity, and GLP-1 also seems to decrease resorption.
PYY’s effect, if there is one, has yet to be determined. GLP-2 has been shown to decrease bone resorption, but it is uncertain whether it affects the osteoclast directly.
GIP has been shown to affect the osteoclast, reducing bone resorption. This has also been shown for GLP-1, while it has also been shown that it increases
differentiation. There is no certain effect of PYY on osteoclasts (Bone figure from Somersault18:24, CCBY-NC-SA 4.0).
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PYY’s Effect on Bones
PYY may exert catabolic effects on bones. Studies in different
populations of patients with different kinds of weight alterations
have suggested that changes in PYY plasma concentrations
modulate bone homeostasis. Elevated fasting PYY was negatively
associated with aBMD in pre-menopausal exercising women
(116) and in women with anorexia nervosa (50). A negative
correlation between elevated PYY and P1NP in young female
athletes with amenorrhea (117) further supports an effect of PYY
on bone homeostasis. Likewise, the higher postprandial PYY
concentration after Roux-en-Y gastric bypass has been suggested
to play a role in the marked bone loss that takes place after
surgery, and exceeds what is expected from the major weight
loss itself. After gastric bypass, CTX increases and this is directly
correlated to the changes seen in PYY (51). In contrast, in patients
losing weight after gastric banding, another bariatric procedure,
both PYY and CTX concentrations were unchanged, supporting
a connection between PYY and bone markers (51).
In addition to these associations in human studies, evidence
from rodent studies supports a role for PYY in the regulation
of bone homeostasis through modulation of both osteoclast and
osteoblast activity. The Y1 receptor has been shown on the
osteoblast, and PYY might exert suppressive effects on osteoblast
activity via these receptors (53). Accordingly, an overproduction
of PYY in transgenic mouse models reduced bone mass, whereas
PYY knockout mice displayed increased bone mass and strength
(54), although the opposite was shown in a study with another
PYY knockout model (55). In addition, selective conditional
deletion of hypothalamic Y2 receptors in adult mice led to
increased bone volume, indicating that the Y2 receptors may also
be involved in bone remodeling (56).
Thus, whereas PYY seems to have robust weight-reducing
effects, exogenous PYY administration might have a detrimental
effect on the bone density.
OSTEOPOROSIS—THERAPEUTIC
POSSIBILITIES IN THE GUT-BONE AXIS
Osteoporosis is a bone disease in which the bone becomes more
fragile. It represents a growing challenge for health care systems
and is also an economic burden, as bone fragility increases
the risk of fracture, which is a major cause of morbidity.
Fractures often require hospitalization and immobilization,
which may cause further complications, and recovery is often
slow and incomplete (118, 119). Pathological fractures arise
from an imbalance in the bone remodeling process, and are
characterized by low bone mass and microarchitectural changes
arising from internal factors (primary osteoporosis), such
as falling levels of estrogen in postmenopausal women, or
external factors (secondary osteoporosis), e.g., malnutrition
(120). Pharmacological treatment of primary osteoporosis
is divided into two classes of drugs with anti-resorptive
and anabolic effects, respectively (121, 122), which is
summarized in Table 2.
Due to lack of efficiency and intolerable side-effects, current
treatment of osteoporosis is limited, and several new drugs are
being developed, targeting specific molecules important for bone
homeostasis. Examples hereof are inhibitors of sclerostin and
dickkopf-1, which are inhibitors of the Wnt signaling pathway,
and inhibitors of cathepsin K, which is secreted from osteoclasts
and important for the resorption process (121, 122).
The strategy of using GLP-2 for the treatment of osteoporosis
has been pursued previously resulting in a series of human studies
investigating acute and chronic effects of daily GLP-2 injections
on bone remodeling (7, 17–19, 76–78, 123). However, despite a
strong inhibition of osteoclast activity and a significant increase
in aBMD after 4 months treatment (17), GLP-2 has not reached
the market as a new drug for the treatment of osteoporosis,
although a GLP-2 analog (teduglutide) was approved by FDA in
2012 for the treatment of SBS because of its beneficial effects on
intestinal function (63). As there are already drugs on the market
based on GLP-1, the effects on bone metabolism may expand
the use of these drugs, or aid the development of drugs more
specifically targeted at bone metabolism. GLP-1 based drugs
have anorexic effects through their activity in the hypothalamus,
which may limit their efficacy as anti-osteoporosis therapy since
food intake plays a pivotal role in the maintenance of strong
bones. Another potential strategy in the development of drugs
based on the hormones in the gut-bone axis, is to target not
one, but two or more receptors. This multi-agonism approach
may have synergistic effects, and there are studies showing
synergistic effects on the treatment of metabolic diseases, such
as T2DM (92, 124, 125). Moreover, one study has shown that
a GIP-oxyntomodulin hybrid peptide (targeting GIP, GLP-1 and
glucagon receptors) had beneficial effects on bone loss in db/db
mice with T2DM (36). As all the discussed hormones have
anabolic and/or anti-catabolic effects on bone metabolism, all of
their cognate receptors are of interest.
In summary, the gut is an important regulator of bone
homeostasis, with several gut-derived factors controlling bone
formation and resorption (Figure 2). The current treatment of
osteoporosis is limited, and as GPCRs in general are excellent
drug targets, it will be exciting to follow whether novel drugs
targeting gut hormone receptors will in the future, reach the
market for the treatment of osteoporosis.
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